Kornimate/medical-research-clean huggingface dataset:
advances in neuropsychological diagnostics

Conditions: Cognitive Impairment; Dementia; Psychiatric Disorder

Summary: this project is aimed at advancing neuropsychological diagnostics, enriching and modernizing the panorama of both clinical and forensic psychometric testing. the rapid socio-demographic changes, the developments of neuropsychological semiotics and nosography, as well as the growing applicative specialization of neuropsychological assessment make it necessary to introduce further tools to satisfy the diagnostic requests in clinical contexts and more recently in the forensic field (i.e., tests to be administered remotely; bedside screeners; domain-specific in-depth tests; tools for assessing testamentary capacity). specifically, the present study aims to: a) develop, calibrate and evaluate the psychometric properties of i and ii level clinical and/or forensic neuropsychological tests evaluating instrumental and non-instrumental functions in a sample of neurologically healthy individuals representative of the italian population ; b) evaluate the cross-sectional and longitudinal clinical usability of the aforementioned tests in clinical samples (patients with neurological and neuropsychiatric pathologies of different etiology).


Eligibility criteria:
inclusion criteria: * clinical populations: clinical diagnosis of either neurological (e.g., vascular and degenerative aetiologies) or psychiatric disorders. * healthy controls: not applicable exclusion criteria: * clinical populations: 1. clinical diagnosis not of interest; 2. severe general medical conditions; 3. uncorrected vision/hearing deficits. * healthy controls: 1. presence of brain disorders; 2. severe general medical conditions; 3. uncorrected vision/hearing deficits.
cycling intervention on symptoms of patients with knee osteoarthritis

Conditions: Osteoarthritis, Knee

Summary: this study is designed to determine the effect of a cycling training program which modulates frontal and sagittal plane knee joint loading with graded increases of q-factor and cycling workrate in persons with symptomatic knee osteoarthritis.

the knee joint is one of the most common joints affected by osteoarthritis, and knee osteoarthritis is primarily observed in the medial compartment. this is in part attributable to the increased load experienced by the medial compartment during level walking. patients with symptomatic knee osteoarthritis exhibit altered gait mechanics; namely a reduced loading response knee extension moment and an increased internal knee abduction moment. as a surrogate measure for medial compartment joint loading, loading response knee abduction moment in level walking has been shown to increase with the severity of knee osteoarthritis. recent gait modification research has shown that increased step-width decreases peak knee abduction moment for persons with knee osteoarthritis. the inter-pedal width of a bicycle or cycle ergometer, known as q-factor, is analogous in cycling to step-width in gait. in contrast to gait, increased q-factor has been shown to increase the knee abduction moment during stationary cycling. modulating sagittal and frontal plane loading of the knee in a graded manner during cycling may promote healthy adaptation to muscle weakness and pain. this adaptation may be manifest through restoration of altered knee joint biomechanics (knee extension moment, knee abduction moment), which, in turn, may also provide benefit to gait mechanics.

Eligibility criteria:
inclusion criteria: * men and women between the ages of 50 and 75 years old. * diagnosed with medial compartment tibiofemoral osteoarthritis in one of their knees. * be able to walk unaided for at least 25 consecutive minutes. * present with knee pain for at least 6 months occurring on a majority of the days in the month, or on most days (more than or equal to 4 of 7 days in a week) in one or both knees for at least 4 months. * osteophytes on knee x-rays. * grade 2 or higher out of a maximum of 4 on a modified kellgren/lawrence grade on the knee radiograph. exclusion criteria: * initial visual analog scale pain scores greater than 7. * diagnosed osteoarthritis of ankles, hips, or symptomatic osteoarthritis of the spine. * arthroplasty of any other lower extremity joint. * bmi value greater than 40 kg/m2. * any major lower extremity injury in the past 6 months. * systemic inflammatory arthritis. * systemic pain conditions. * neurological conditions that impact gait or cycling. * pregnant or nursing women. * major cardiovascular disease with an exercise limitation prescribed by a physician. * steroid injection at the knee within the previous 3 months.
post-transplant thrombotic microangiopathy: evaluation of outcomes at the bologna kidney transplant centre

Conditions: Microangiopathy; Kidney Transplant

Summary: it is a retrospective-prospective, single-centre, non-pharmacological, retrospective tissue study carried out for scientific and health protection purposes. it involves the systematic collection of clinical information from patients diagnosed with pt-tma

the primary objective is to calculate the incidence of pt-tma in a large cohort of kidney transplant patients and to assess the association between pt-tma and renal transplant outcome. it provides for the systematic collection of clinical information of patients with a diagnosis of pt-tma, starting from 01/06/2016 until the approval of the study by the ethics committee and the issuance of the authorisation by the director general of the irccs; the evaluation of the prospective data will be carried out starting from the approval of the study by the ethics committee and the issuance of the authorisation by the director general of the irccs and will continue for 10 years. patients enrolled prospectively will be treated according to clinical practice, in accordance with the judgement of the physician

Eligibility criteria:
inclusion criteria: * age ≥ 18 years * living kidney transplant recipient, brain death cadaver donor, cardiac death cadaver donor, single kidney transplant, double kidney transplant, combined kidney transplant * acquisition of informed consent to participate in the study and to process personal, special and genetic data exclusion criteria: -
a study of amr101 to evaluate its ability to reduce cardiovascular events in high-risk patients with hypertriglyceridemia and on statin

Conditions: Cardiovascular Diseases

Summary: amr101 (icosapent ethyl \[ethyl-epa\]) is a highly purified ethyl ester of eicosapentaenoic acid (epa) developed by amarin pharma inc. for the treatment of cardiovascular disease in statin-treated patients with hypertriglyceridemia. the purpose of this study was to evaluate whether this drug, combined with a statin therapy, will be superior to the statin therapy alone, when used as a prevention in reducing long-term cardiovascular events in high-risk patients with mixed dyslipidemia.


Eligibility criteria:
inclusion criteria: * men and non-pregnant or sterile women ages 45 and older * hypertriglyceridemia * on statin therapy for at least four weeks * either having established cardiovascular disease or at high risk for cardiovascular disease exclusion criteria: * severe heart failure * any life-threatening disease other than cardiovascular disease * active severe liver disease * hemoglobin a1c \>10.0% * poorly controlled hypertension * planned coronary intervention (such as stent placement or heart bypass) or any non-cardiac major surgical procedure * known familial lipoprotein lipase deficiency (fredrickson type i), apolipoprotein c-ii deficiency, or familial dysbetalipoproteinemia (fredrickson type iii) * known hypersensitivity to the study product, fish and/or shellfish, or placebo * history of acute or chronic pancreatitis * patients are excluded if using the following medications: * pcsk9 inhibitors * niacin \>200 mg/day or fibrates; * any omega-3 fatty acid medications ; * dietary supplements containing omega-3 fatty acids (e.g., flaxseed oil, fish oil, krill oil, or algal oil); * bile acid sequestrants

Keywords: coronary artery disease myocardial ischemia coronary disease heart diseases acute coronary syndrome cardiovascular diseases arteriosclerosis arterial occlusive diseases vascular diseases angina pectoris chest pain anticholesteremic agents hypolipidemic agents lipid regulating agents hypertriglyceridemia omega-3 fatty acids statin triglycerides epa docosahexaenoic acid fish fatty acids fibrates niacin lipids lipoprotein atorvastatin lovaza simvastatin lovastatin pravastatin fluvastatin rosuvastatin trilipix vytorin simcor ezetimibe zetia ethyl-epa ethyl icosapentate crestor zocor lipitor ldl hdl cholesterol dyslipidemia amr101 cardiovascular disease, unspecified vascepa icosapent ethyl
implementation of the nurse navigation program

Conditions: Intestinal Cancer

Summary: this study was conducted as a randomized controlled intervention study with repetitive measurements in a pretest-posttest order to examine the effect of nurse navigation program on compliance, quality of life and prevention of complications in patients with intestinal stoma. the study was completed with 30 experimental and 28 control group patients with intestinal stoma in six hospitals, two of which are training and research hospitals, located in gaziantep city center, between january 1 and december 31, 2021. while counseling, remote support, written and visual trainings, informative messages, phone calls, and appointment scheduling were applied to the patients in the experimental group within the scope of the nurse navigation program, the patients in the control group received standard care

this study was conducted as a randomized controlled intervention study with repetitive measurements in a pretest-posttest order to examine the effect of nurse navigation program on compliance, quality of life and prevention of complications in patients with intestinal stoma. the study was completed with 30 experimental and 28 control group patients with intestinal stoma in six hospitals, two of which are training and research hospitals, located in gaziantep city center, between january 1 and december 31, 2021. while counseling, remote support, written and visual trainings, informative messages, phone calls, and appointment scheduling were applied to the patients in the experimental group within the scope of the nurse navigation program, the patients in the control group received standard care. the patients were evaluated using the patient information form, stoma complications evaluation form, stoma-related problems experienced form, ostomy compliance scale, and stoma quality of life scale at the first interview, at the third and sixth months.

Eligibility criteria:
inclusion criteria:with intestinal stoma * having no mental handicap or perception problems and no communication difficulties * no psychiatric disease * 18 years old and over * literate * capable of using a smartphone * no vision and hearing problems * those who have the physical ability to change the stoma bag themselves. * patients with intestinal stoma for a maximum of two months were included in the study. exclusion criteria: * after agreeing to participate in the research, wanting to leave, * those who died during the research process, * the stoma was closed during the research process, * patients whose communication could not be maintained during the research process

Keywords: nursing, navigation program, stoma, compliance
vah versus va for salvage therapy of r/r-aml

Conditions: Venetoclax Combined With Azacitidine Plus Homoharringtonine; Venetoclax Combined With Azacitidine

Summary: this is a prospective, multi-center, phase 3 randomized controlled clinical study comparing vah and va regimens for the salvage treatment of the patients with relapsed/refractory aml. approximately 164 subjects will be randomized in a 1:1 ratio to receive vah regimen (82 subjects) or va regimen (82 subjects) for salvage therapy. randomization is done with permuted blocks (block size four), and implemented through an interactive web-based response system. vah regimen: ven begins at 100 mg on day 1 and increases stepwise over 3 days to reach the target dose of 400 mg (100 mg, 200 mg, 400 mg); dosing is continued at 400 mg per day from day 4 through day 14; azacitidine (75 mg/m²) is administered subcutaneously on days 1-7, and hht (1 mg/m²) on days 1-7. va regimen: the use of ven is just the same as it dose in vah regimen except lasting for 28 days. the use of azacitidine is exactly the same as vah group does. the primary endpoint was overall response rate (orr) after 2 cycles of trial therapy. the secondary endpoints were crc after 2 cycles of trial therapy, overall survival (os), event-free survival (efs) and relapse at 2 year, and safety.


Eligibility criteria:
inclusion criteria: 1. patients with relapsed/refractory aml the diagnosis of aml or relapsed aml was based on the criteria from nccn, defined as recurrence of blasts in the peripheral blood (pb) or bone marrow (bm) blasts \> 5% or development of extramedullary disease of patients after achieving a cr. refractory aml was defined as no composite complete remission (crc) and a reduction in bone marrow blasts of less than 50% after one cycle or no crc after two cycles. 2. age 18 to 65 years old with eastern cooperative oncology group (ecog) performance status 0-2 3. sign informed consent form, have the ability to comply with study and follow-up procedures exclusion criteria: 1. acute promyelocytic leukemia (aml subtype m3) 2. previous exposure to the treatment of ven-based regimen 3. life expectancy less than 30 days after salvage therapy 4. cardiac dysfunction (particularly congestive heart failure, unstable coronary artery disease and serious cardiac ventricular arrhythmias requiring antiarrhythmic therapy) 5. respiratory failure ( pao2 ≤60mmhg) 6. hepatic abnormalities (total bilirubin ≥2 times the upper limit of normal \[uln\], alanine aminotransferase or aspartate aminotransferase ≥2 times the uln) 7. renal dysfunction (creatinine ≥2 times the uln or creatinine clearance rate \< 30 ml/min) 8. ecog performance status 3, 4 or 5 9. with any conditions not suitable for the trial (investigators' decision) 10. active acute or chronic graft-versus-host disease (gvhd). active acute gvhd or chronic gvhd was defined as gvhd requiring either at least 1 mg/kg per day of prednisone (or equivalent) or treatment beyond systemic corticosteroids. 11. patients with pregnancy

Keywords: relapsed/refractory acute myeloid leukemia
placebo controlled trial to evaluate zinc for the treatment of covid-19 in the outpatient setting

Conditions: Corona Virus Infection

Summary: this is a randomized, double-blind, placebo-controlled trial to assess the efficacy of zinc in a higher risk covid-19 positive outpatient population.

zinc, a micronutrient, appears to have anti-viral properties with various mechanisms of action depending on the concentration zinc supplementation has been reviewed extensively for use in the common cold, and has been shown to reduce the duration of symptoms. in-vitro studies have shown zinc can inhibit rna-dependent rna polymerase (rdrp) in coronavirus, which is typically a conserved region in the viral genome. in-vitro experiments have also shown that lung epithelium in a zinc depleted state can become susceptible to apoptosis and loss of barrier function, increasing permeability, which can lead to acute respiratory distress syndrome (ards). if a patient can travel to st. francis hospital they can have a covid test on site at a designated st. francis testing location. the covid test will be resulted via a rapid covid (point of care device) or at a local lab. patients who are unable to travel to st. francis hospital or one of the outpatient practices, will be allowed to enroll remotely. patients are eligible to enroll within 72 hours of a positive covid-19 test result. study medications will be mailed to the patient overnight after being enrolled.

Eligibility criteria:
inclusion criteria: * able to read and understand informed consent. * high initial clinical suspicion by physician based on signs and symptoms (fever, cough, myalgias, fatigue, shortness of breath) followed by confirmation of covid-19 diagnosis * any gender * age 60 years and older * age 30-59 years with one or more of the following: * abnormal lung exam * abnormal oxygen saturation \<95% * abnormal chest x-ray or chest ct * persistent fever \>100.4 degrees fahrenheit * one of the following co-morbidities: hypertension, diabetes mellitus, history of coronary artery disease, chronic kidney disease (ckd), asthma, copd, current or former smoker, or morbid obesity (body mass index ≥35) exclusion criteria: * severe covid-19 requiring admission for inpatient treatment * need for any oxygen supplementation * need for mechanical ventilatory support * history of oxygen supplementation dependency * history of cancer with ongoing chemotherapy or radiation therapy * known hypersensitivity to zinc * severe renal disease: glomerular filtration rate \<30ml/min

Keywords: covid-19 zinc
management of systolic blood pressure during thrombectomy by endovascular route for acute ischaemic stroke

Conditions: Stroke; Embolus Cerebral; Blood Pressure

Summary: stroke is the third most common cause of death in new zealand and is one of the leading causes of long-term disability at all ages. a life-saving clot retrieval procedure can save lives and prevent disability of patients with ischaemic stroke who get to hospital in time. in new zealand, 90% of clot retrieval procedures are performed under general anaesthesia. many anaesthetic drugs can affect blood pressure (bp) and blood flow within the brain. increasing bp during the procedure could provide additional benefits in this devastating disease. a large trial is needed to investigate bp management during clot retrieval.

internationally stroke ranks second among all causes of disability and is adding to considerable worldwide healthcare burden. over the last 5 years a new procedure to remove clots (endovascular thrombectomy - evt) has been effective for the treatment of acute large strokes, with significant reductions in long term patient disability compared to standard treatment. however, there minimal guidance on blood pressure management during the procedure. the brain is especially vulnerable to low blood pressure during the acute stroke period due to low blood supply, impairment of how the brain regulates blood flow and further falls in blood flow to the brain. high blood pressure may be beneficial due to increased blood flow in areas at risk during this time. it could be harmful due to brain injury process, swelling, and bleeding into the brain. conversely, relatively low blood pressure could be harmful. current evidence is limited to large observational studies. this randomised controlled study will examine the safety and efficacy of two systolic blood pressures (sbp) management arms during general anaesthesia for evt on outcomes in patients with acute ischaemic stroke.

Eligibility criteria:
inclusion criteria: * patients diagnosed with anterior circulation stroke (ica or proximal m1 or m2 segment of mca) treated with ecr within 6 hrs of stroke onset and ecr patients presenting within 6-24 hours and favourable penumbra on perfusion scanning (see criteria 1-3). additional criteria in the 6 to 24-hour window. 1. 'wake up' stroke; ct with no (or at most minimal) acute infarction or 2. patient 80 years or older (nihss of 10 and infarct volume less than 21 ml on dwi or ct perfusion-cbf) 3. patient less than 80 years (nihss of 10 and infarct volume less than 31 ml on dwi or ct perfusion-cbf nihss of 20 and infarct volume less than 51 ml on dwi or ct perfusion-cbf). exclusion criteria: * rescue"' procedures eg acute ischaemic stroke associated with major medical procedures such as coronary artery stenting and coronary artery bypass * pre-stroke mrs\>=3 * not having ga * terminal illness with expected survival \<1 year * pregnancy * cardiovascular conditions where bp targeting will be contra-indicated * unable to participate in 3-month follow up
effect of ciclesonide on quality of life in patients with moderate persistent asthma (21 to 65 y) (by9010/ar-101)

Conditions: Asthma

Summary: the aim of the study is to compare the effect of ciclesonide on quality of life, pulmonary function and time to first exacerbation in patients with moderate persistent asthma. ciclesonide will be administered once daily in the evening at two dose levels. the study duration consists of a baseline period (2 weeks) and a treatment period (8 weeks).


Eligibility criteria:
main inclusion criteria: * written informed consent * good health with the exception of asthma * clinical diagnosis of moderate persistent asthma during the last 6 months prior to visit b0 * pre-treatment with inhaled corticosteroids dose equivalent to 250 - 500 mcg bdp / day at stable dosing during the last 4 weeks prior to visit b0, concomitant or not to short-acting beta2-agonists treatment as rescue medication * fev1 ≥ 70% and ≤ 90% predicted measured at least 4 h after the last use of rescue medication at visit b0 * reversibility ≥ 12% and ≥ 200 ml in b0, b0 or t0, after inhalation of 400 mcg of salbutamol * patients compliant to recommended pre-treatment main exclusion criteria: * concomitant severe diseases or diseases which are contraindications for the use of inhaled steroids * chronic obstructive pulmonary disease (copd) * hospitalization within previous four weeks from baseline * hospitalization due to asthma within the last twelve months * asthma exacerbation within two months previous to baseline * history of almost fatal asthma at any moment * pregnancy, breast feeding, intention to become pregnant during the course of the study or lack of safe contraception in pre-menopausal women * exacerbation of asthma within 2 months prior to entry into the baseline period * use of systemic steroids up to 2 months (injectable depot steroids 6 months) before entry into the baseline period, or more than 3 times during the last 6 months

Keywords: asthma quality of life ciclesonide
standard corneal collagen crosslinking versus transepithelial corneal crosslinking by iontophoresis of riboflavin

Conditions: Keratoconus

Summary: the standard cxl technique involves removal of the epithelium to enable riboflavin to penetrate into stromal tissue, to avoid epithelial debridement and increasing the patient's comfort and safety transepithelial corneal crosslinking (cxl) was suggested. iontophoresis of riboflavin is one of approach for riboflavin impregnation. in this study, the investigators compared the results of standard corneal crosslinking (cxl) and transepithelial cxl via iontophoresis of riboflavin after 24 months follow up.


Eligibility criteria:
inclusion criteria: * documented progressive kc (by pentacam and/or corneal topography imaging). * a clear central cornea. * a minimal corneal thickness of ≥ 400 µm at the thinnest corneal location (pentacam imaging). * minimal snellen corrected distance visual acuity of ≥ 0.4. * patient age of ≥ 18 years. exclusion criteria: * corneal scarring. * history of epithelial healing problems. * history or presence of ocular infection (such as herpes keratitis) * pregnancy and/or breastfeeding.

Keywords: collagen crosslinking (cxl) standard corneal crosslinking (cxl) transepithelial cxl iontophoresis riboflavin